A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Robin Glasco, MBA, Spencer Stuart, examines the crucial role of data in addressing urgent challenges in health care while inherent and systemic biases coexist, complicating efforts to achieve equity.
Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.
Alcohol was first identified as a carcinogen almost 40 years ago, by the World Health Organization's International Agency for Research on Cancer.
How does age, sex, comorbidity, and screening history influence the cost-effectiveness of continuing colorectal cancer (CRC) screening in older adults?
Monitoring thyroid dysfunction from HIV could prevent hypothyroidism in the few patients who have these abnormalities.
Acknowledging the disparity in pulse oximetry implicates a $2 billion industry that has faced stricter regulations in recent years in an attempt to address bias in the development and testing of these devices, the authors stated.
Compared with female patients, male patients with eosinophilic esophagitis have higher rates of complications, including esophageal obstruction, food impaction, and rupture, highlighting potential gender differences in disease severity.
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).
People living with HIV in California were highly satisfied with telephone visits during the height of the COVID-19 pandemic and wanted to continue them in their regular care.
Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient concerns about technology understanding and insurance coverage, as well as the reliance on traditional tissue biopsies, emphasizing the benefits of combining liquid and tissue biopsies to improve treatment outcomes and clinical trial eligibility.
Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.
Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more responsive to immune treatments.
Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed.
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension (PAH).
The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.
When compared with auditory stimulus, patients with glaucoma had slower response times to visual stimulus.
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia.
A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
The Employee Retirement Income Security Act (ERISA) Industry Committee filed a legal challenge against the Minnesota Department of Commerce, arguing that Minnesota’s Pharmacy Benefit Manager (PBM) Licensure and Regulation Act illegally interfered with employer-sponsored health plans by restricting plan design options and increasing costs.
Song Park, MD, University of Washington Medicine, advocates for more user-friendly technology to support equitable skin cancer care access.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The VET PFAS Act could help older veterans with toxic exposure attain the medical treatment they need by expanding eligibility.
Lockdowns instituted due to the COVID-19 pandemic could have brought about exacerbated immune responses in people living with HIV.
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.
Top content from the Association of Cancer Care Centers (ACCC) fall conference included topics on patient participation, new cancer care programs, prior authorization processing, and more.
Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, less invasive diagnostics, with key applications in early detection, predictive biomarker identification, treatment response monitoring, resistance mechanism assessment, and minimal residual disease detection.
